HDAC9 and Miyoshi myopathy: The pan-HDAC inhibitor panobinostat showed promising overall response rates in combination with bortezomib and dexamethasone for bortezomib-refractory MM patients in the PANORAMA 1 clinical trial, which led to its FDA accelerated approval in 2015 [8].